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Summary

Background Respiratory syncytial virus (RSV) infection is an important cause of pneumonia mortality in young
children. However, clinical data for fatal RSV infection are scarce. We aimed to identify clinical and socioeconomic
characteristics of children aged younger than 5 years with RSV-related mortality using individual patient data.
Methods In this retrospective case series, we developed an online questionnaire to obtain individual patient data for
clinical and socioeconomic characteristics of children aged younger than 5 years who died with community-acquired
RSV infection between Jan 1, 1995, and Oct 31, 2015, through leading research groups for child pneumonia identified
through a comprehensive literature search and existing research networks. For the literature search, we searched
PubMed for articles published up to Feb 3, 2015, using the key terms “RSV”, “respiratory syncytial virus”, or
“respiratory syncytial viral” combined with “mortality”, “fatality”, “death”, “died”, “deaths”, or “CFR” for articles
published in English. We invited researchers and clinicians identified to participate between Nov 1, 2014, and
Oct 31, 2015. We calculated descriptive statistics for all variables.
Findings We studied 358 children with RSV-related in-hospital death from 23 countries across the world, with data
contributed from 31 research groups. 117 (33%) children were from low-income or lower middle-income countries,
77 (22%) were from upper middle-income countries, and 164 (46%) were from high-income countries. 190 (53%) were
male. Data for comorbidities were missing for some children in low-income and middle-income countries. Available
data showed that comorbidities were present in at least 33 (28%) children from low-income or lower middle-income
countries, 36 (47%) from upper middle-income countries, and 114 (70%) from high-income countries. Median age for
RSV-related deaths was 5·0 months (IQR 2·3–11·0) in low-income or lower middle-income countries, 4·0 months
(2·0–10·0) in upper middle-income countries, and 7·0 months (3·6–16·8) in high-income countries.
Interpretation This study is the first large case series of children who died with community-acquired RSV infection.
A substantial proportion of children with RSV-related death had comorbidities. Our results show that perinatal
immunisation strategies for children aged younger than 6 months could have a substantial impact on RSV-related
child mortality in low-income and middle-income countries.
Funding Bill & Melinda Gates Foundation.
Copyright © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.

Introduction
Respiratory syncytial virus (RSV) infection is the primary
pathogen identified in children with acute lower respiratory
tract infection during the first year of life.1–4 RSV-related
acute lower respiratory tract infection is an important
cause of death in young children (aged younger than
5 years); approximately 48 000–74 500 children in this age
group died in hospital with the condition in 2015.5 About
99% of RSV-related childhood mortality occurs in
developing countries.5 Although RSV-related mortality in
children poses an important global health problem, clinical
data for global RSV-related mortality are scarce. Data
suggest that most RSV-related childhood mortality occurs
www.thelancet.com/lancetgh Vol 5 October 2017

during the first year of life.6–8 Although the case fatality rate
is highest in children with underlying conditions, such as
congenital heart disease, chronic lung disease, Down’s
syndrome, or premature birth,7–13 most cases of lifethreatening RSV infection occur among previously healthy
children.14–16 This finding suggests that in settings without
intensive care facilities, otherwise healthy children could
also be at risk of dying from RSV infection. A study from
Argentina16 reported that poor access to intensive care was
associated with RSV-related death.
RSV-related mortality in young children has primarily
been described sporadically in studies10,11,14,17 from intensive
care units in high-income or middle-income countries.
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Research in context
Evidence before this study
Respiratory syncytial virus (RSV) infection is a leading cause of
global acute lower respiratory tract infection in young children.
It was associated with 48 000–74 500 in-hospital deaths in
children aged younger than 5 years in 2015, with 99% of these
deaths occurring in developing countries. However, individual
patient data for RSV-related deaths are scarce. We searched
PubMed for articles published in English up to July 7, 2017, using
search terms related to RSV infection, pneumonia, and childhood
mortality. We found case series of RSV-related child deaths that
reported 35 cases or fewer.
Added value of this study
We did, to our knowledge, the first case series of children who
died with RSV infection to define clinical and socioeconomic
characteristics of RSV-related mortality. We searched the
literature using PubMed for “RSV”, “respiratory syncytial virus”,
or “respiratory syncytial viral” combined with “mortality”,

To date, the largest case series11 of 35 RSV-related deaths
was reported from an intensive care unit in the UK, with
numbers smaller than 35 having been reported in other
studies.2,16,18,19 In 2015, the WHO’s Product Development
for Vaccines Advisory Committee identified RSV as “a
pathogen for which there is major vaccine pipeline
activity”, with a vaccine likely to be available in the next
5–10 years.20
Two broad approaches to RSV immunisation are being
considered in young children: maternal immunisation
for children aged younger than 6 months and paediatric
vaccines for children aged older than 6 months. A good
understanding of the age distribution of RSV-related
deaths is likely to assist in development of an evidence
base to inform vaccine policy, particularly in low-income
and middle-income settings.21
Previous reports of RSV-related mortality in young
children described studies done in one centre, region, or
country. None of them were large enough to draw robust
conclusions on the clinical and socioeconomic profile
of children who die with community-acquired RSV
infection globally. To gain insight into the clinical
characteristics of RSV-related mortality in young
children, we initiated the RSV Global Online Mortality
Database (RSV GOLD) study with the aim to gather
available retrospective data for fatal community-acquired
RSV infections across the world.

Methods

Study design and patients
RSV GOLD is a global study that retrospectively analysed
individual data for children aged 0–59 months who died
with community-acquired RSV infection between Jan 1,
1995, and Oct 31, 2015. We identified research groups
through a comprehensive literature search on PubMed

“fatality”, “death”, “died”, “deaths”, or “CFR” for articles
published up to Feb 3, 2015, in English, to identify research
groups with relevant cases and obtained additional cases
through existing research networks. We report on
358 in-hospital deaths with laboratory-confirmed RSV infection
from 23 countries across the world. A substantial proportion of
in-hospital RSV-related deaths occurred in children with
pre-existing comorbidities. Most children in low-income and
middle-income countries were aged younger than 6 months at
the time of death.
Implications of all the available evidence
This study is the first case series of children who died with RSV
infection in hospital, giving insight into the clinical and
socioeconomic background of children with RSV-related death.
Young age at death supports the concept that maternal
vaccination against RSV infection could be an effective strategy
to prevent RSV-related childhood mortality.

(for articles published up to Feb 3, 2015) using the key
terms “RSV”, “respiratory syncytial virus”, or “respiratory
syncytial viral” combined with “mortality”, “fatality”,
“death”, “died”, “deaths”, or “CFR”. We limited the search
to papers written in English with the abstract and full text
available. We invited authors of scientific, peer-reviewed
papers reporting RSV-related mortality in children to
collaborate. Additionally, we obtained unpublished
individual patient data from researchers and clinicians
who we identified via research networks. We invited
researchers and clinicians to participate in this study
between Nov 1, 2014, and Oct 31, 2015. We included data
for children with laboratory-confirmed RSV infection
and excluded cases of nosocomial or post-stem cell
transplantation RSV infection. Since this study only used
anonymised secondary data, the institutional research
board of the University Medical Centre Utrecht waived
the requirement for parental informed consent.

Procedures
We collected data using an online questionnaire designed
by a group of investigators (NMS, LJB, HN, FPP, BDG,
and DEG). The questionnaire aimed to collect information
about clinical and socioeconomic charac
teristics of
children with RSV-related mortality. Characteristics of
interest were based on risk factors for RSV-related and
pneumonia-related mortality as described in the literature
and on expert opinion (appendix).
We carefully validated patient information by direct
communication with participating researchers for data
entry errors, missing variables, and conflicting data. We
deemed age at death within 0–59 months, laboratoryconfirmed RSV diagnosis, and community-acquired RSV
infection minimum essential data for inclusion. After
assessment of data quality, we excluded children if
www.thelancet.com/lancetgh Vol 5 October 2017
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nosocomial infection could not be ruled out on the basis
of available clinical information or if death occurred
before 1995. We sent additional questions about
admission to paediatric intensive care units and
availability of mechanical ventilation to the participating
researcher if this information could not be extracted
from the shared data.
We defined the following patient populations: children
with comorbidities, healthy term children, and preterm
children without other comorbidities (healthy preterm
children). Children with comorbidities had at least
one underlying disease, such as congenital heart disease,
a genetic or chromosomal disorder, HIV infection, or
active tuberculosis. Healthy term children were born
without comorbidities at 37 weeks’ gestational age or
later and healthy preterm children were born without
comorbidities at earlier than 37 weeks’ gestational age.
When data for comorbidities or prematurity were not
recorded, we assumed that the children were healthy
term. We categorised countries as high income, upper
middle income, lower middle income, or low income on
the basis of the World Bank classifications for 2016.22
We considered Hong Kong and Taiwan high-income
countries in line with the World Bank classification. The
composite variable neurological disease consisted of
neurodevelopmental, neuromuscular, and other neuro
logical disease, such as epilepsy or encephalopathy.

NMS and LJB had full access to all the data in the study
and the corresponding author had final responsibility for
the decision to submit for publication.

Results
The literature search resulted in 1154 publications
(figure 1). From these publications, we identified
85 research groups, which we complemented with
research groups identified through existing research
networks, particularly through the RSV Global
1154 potentially eligible
studies identified by
database search

979 excluded after title and abstract
screening
175 studies identified for
full-text screening

93 studies identified
for research group
selection

85 research groups
identified
67 research groups identified via
research networks

www.thelancet.com/lancetgh Vol 5 October 2017

19 excluded as same research groups
133 research groups
contacted
68 excluded as no response
45 literature search
23 networks
65 research groups
responded
34 excluded
21 no RSV mortality data available
3 literature search
18 networks
13 data not contributed
5 literature search
6 networks
2 lost contact
31 research groups
contributed data
for 451 children
93 excluded after assessment of data
quality
75 nosocomial RSV
6 duplicate entry
2 no laboratory-confirmed RSV
diagnosis
2 from 1994
1 aged 5 years or older
7 posthospital discharge deaths
of unknown cause
358 children included

Role of the funding source
The funder had no role in study design, data collection,
data analysis, data interpretation, or writing of the report.

82 excluded after full-text screening
4 full text not available
11 review or modelling study
11 done before 1995
38 no RSV mortality
3 aged 5 years or older
8 post-transplant RSV
7 nosocomial RSV

8 excluded as published by same
research group

Statistical analysis
We calculated descriptive statistics for all variables. We
provide frequencies and proportions for categorical
variables. We report the summary results for continuous
variables as medians with IQRs. We analysed data by
World Bank income regions. Additionally, we analysed
data separately for children with comorbidities, healthy
term children, and healthy preterm children. Using WHO
child growth standards,23 we calculated Z scores for weight
for age, height for age, and weight for height. We did not
correct weight for age for gestational age.
To rule out bias, we did sensitivity analyses excluding
cases with missing data for prematurity or comorbidities
to test our assumption that children with missing data
were healthy term. Similarly, we analysed to what extent
our results were sensitive to the contribution of a large
number of cases from Argentina and Kenya by doing
analysis without these countries. We tested meaningful
subgroup differences for significance with KruskalWallis or χ² statistical tests. We did further paired testing
between subgroups using Mann-Whitney U or χ² tests
with Bonferroni correction for multiple testing. We did
not test subgroup differences of results presented in
the appendix for significance. We did all statistical
analyses with SPSS statistical software (version 22.0).

Faculty of Medicine and Chinese
University of Hong KongUniversity Medical Center
Utrecht Joint Research
Laboratory of Respiratory Virus
and Immunobiology, Chinese
University of Hong Kong,
Shatin, New Territories, Hong
Kong Special Administrative
Region, China (T F Leung MD);
Health Secretariat of the city of
Belo Horizonte, Belo Horizonte,

Figure 1: Study selection
RSV=respiratory syncytial virus.
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Figure 2: Locations of the respiratory syncytial virus-related deaths in young children included in the analysis
Numbers of deaths are given for each country included.

Epidemiology Network.5 We obtained data for
451 children with RSV-related mortality from the
31 research groups that shared data. We obtained both
published and unpublished cases. Using original
publications to contact research groups, we estimated
that we could have missed a maximum of 140 cases from
the published literature as most researchers who did not
respond to our invitation to participate had reported
solitary cases of RSV-related mortality: in 28 publications,
the number of potential RSV-related deaths was
mentioned and in 15 (54%) of those, one or two RSVrelated deaths were described. Many non-responders
were research groups from high-income countries
(41 [60%] of 68) and had published their results between
2010 and 2015 (21 [47%] of 45). Publications used to
identify research groups that contributed data are shown
in the appendix. After initial assessment of the
451 children, we excluded 93 (21%). Most exclusions
were associated with nosocomial RSV infection. We
excluded six (1%) duplicate entries. We included
358 (79%) children with RSV-associated mortality
originating from 23 different countries across the world
(figure 2, appendix). RSV diagnosis was established
most often by immunofluorescence or PCR (appendix).
PCR was mostly used in children who died after 2005.
Clear seasonality with an annual peak was reported in
18 (78%) of the 23 countries.
117 (33%) children were from low-income or lower
middle-income countries, 77 (22%) were from upper
middle-income countries, and 164 (46%) were from
high-income countries (table). 190 (53%) children were
male; we observed no sex differences between countries of

different incomes. Children from high-income countries
had a higher median age at death than did those in
low-income or lower middle-income countries and
children from high-income countries had stayed in hospital
for a longer period and were more often admitted to a
paediatric intensive care unit than those from upper
middle-income countries or low-income or lower
middle-income countries. Median time between onset of
symptoms and death was longer in children from highincome countries (21·0 days [IQR 12·0–37·0]) than in
those from low-income or lower middle-income countries
(9·5 days [7·0–16·8]) or upper middle-income countries
(10·0 days [8·0–14·0]; appendix).
We analysed the prevalence of comorbidities in our
study (table) and distinguished clinical characteristics of
children with and without comorbidities (appendix).
Data for comorbidities were missing for some children.
Available data showed that comorbidities were present in
at least 183 (51%) children. Congenital heart disease was
the most frequent comorbid condition identified. The
proportion of children with comorbidities was similar
during sensitivity analyses when children with missing
data (for comorbidities and gestational age) were
excluded, except that the proportion with comorbidities
in low-income or lower middle-income countries was
more than doubled (appendix). Specific information
about the presence of comorbidities and prematurity was
available in 243 (68%) children. The proportion of
missing information about comorbidities and
prematurity was similar for children aged younger than
6 months at the time of death (54 [30%] of 178) and older
children (61 [34%] of 180).
www.thelancet.com/lancetgh Vol 5 October 2017
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Low-income or lower
middle-income
countries (n=117)
Male sex
Age at death (months)
Younger than 6 months at death
Prematurity§

58 (50%)
5·0 (2·3–11·0)
68 (58%)

Upper middle-income
countries (n=77)

0·976

38 (49%)

0·973
0·893

4·0 (2·0–10·0)
44 (57%)

p value† High-income countries
(n=164)
0·247
0·023
0·014

94 (57%)
7·0 (3·6–16·8)
66 (40%)

p value‡

0·199
0·006
0·003

0·083

12 (16%)

0·043

45 (27%)

0·000

38·0 (38·0–39·0); n=22

0·144

38·0 (34·5–38·0); n=38

0·250

38·1 (32·1–40·0); n=80

0·688

Comorbidity§

33 (28%)

0·008

36 (47%)

0·001

Oxygen saturation on room air at
hospital admission (%)

92·0% (85·8–97·3); n=94 0·022

Weight for age Z score of less than –2

64/111 (58%)

Contact with health-care provider
before admission to hospital

28/65 (43%)

Gestational age (weeks)

Time between onset of symptoms and
admission (days)
Length of stay in hospital (days)
Availability of intensive care unit

9 (8%)

p value*

0·000

89·0% (76·5–91·0); n=37

0·924

33/58 (57%)

0·370

49/99 (50%)

0·236

0·870

17/38 (45%)

0·123

41/68 (60%)

0·047

5·0 (3·0–7·0); n=71

0·002

3·0 (2·0–6·0)

0·000

28 (24%)

114 (70%)

87·0% (85·0–94·0); n=47 0·448

0·000

3·0 (2·0–4·0); n=45
7·0 (3·0–11·5)
75 (97%)

0·387
0·000
0·038

3·0 (1·0–5·0); n=135
15·0 (7·0–32·0); n=149
164 (100%)

0·001
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0·000
0·000
0·000

Intensive care unit admission

23/116 (20%)

0·000

27/56 (48%)

0·000

152 (93%)

0·000

Mechanical ventilation

23/114 (20%)

0·000

33/60 (55%)

0·000

138/155 (89%)

0·000

Urban living area

22/66 (33%)

0·000

39/40 (98%)

0·867

129/133 (97%)

0·000

At least one sibling present in household 30/39 (77%)

0·122

16/17 (94%)

0·003

62/109 (57%)

0·027

Time of death relative to RSV seasonality
Death during RSV season
Death within 1 month before or after
RSV season

61/79 (77%)

0·004

35/64 (55%)

0·000

122/134 (91%)

0·005

7/79 (9%)

0·050

13/64 (20%)

0·001

7/134 (5%)

0·303

Data are n (%), median (IQR), or n/N (%). Statistical comparisons with Mann-Whitney U test or χ² test with p values of less than 0·0167 taken to be significant according to
Bonferroni correction for multiple testing. RSV=respiratory syncytial virus. *Low-income or lower middle-income country versus upper middle-income country.
†Upper middle-income country versus high-income country. ‡Low-income or lower middle-income country versus high-income country. §Considered absent when missing.

Table: Clinical characteristics and risk factors in RSV-related child deaths

We analysed how the presence of comorbidities
affected age at death (figure 3). Most healthy term and
healthy preterm children were aged younger than
6 months at the time of RSV-related death (appendix).
The proportion of children aged younger than 6 months
at the time of death was even larger when only children
with complete data for comorbidity and gestational age
status were included than when all children were
included (appendix). Age at death of children with
comorbidities from high-income countries was higher
than that of those from low-income or middle-income
countries.
We analysed the proportion of children with low
weight for age. More than half of all children had a
weight for age of less than –2 SDs (table). In highincome countries, this finding was mainly explained by
a large proportion of preterm children and children
with comorbidities. Only eight (28%) of 29 healthy
term children in high-income countries had low weight
for age compared with eight (89%) of nine healthy
preterm children and 33 (54%) of 61 children with
comorbidities (appendix). By contrast, in the other two
income regions, we found a high proportion (≥48%) of
low weight for age in all three children groups,
including healthy term infants.
www.thelancet.com/lancetgh Vol 5 October 2017

Data for co-infection were scarce. Microbiological
data other than RSV diagnosis were sparsely available.
We identified co-pathogens in 70 children, with
22 (31%) who tested positive for two or more pathogens
besides RSV (data not shown). Positive blood cultures
were reported in four (6%) children (two [3%] with
Pseudomonas aeruginosa, one [1%] with Klebsiella spp,
and one [1%] with Staphylococcus aureus).
Data from Argentina (78 [22%]) and Kenya (43 [12%])
contributed to about one third of all RSV-related deaths
(121 [34%]). We did a sensitivity analysis excluding these
data. The results from these analyses showed a higher
age at death for children from high-income countries
(10·0 months [4·0–24·0]) than from upper middleincome (4·0 months [2·0–10·0]) or low-income or lower
middle-income (4·0 months [2·2–7·0]) countries, which
was the same trend as for the main analysis. Other
clinical characteristics, including sex and the proportion
of prematurity or comorbidities, were also unchanged
from the main analysis (data not shown).

Discussion
Severe RSV infection is one of the major causes of
global mortality in young children, with 99% of deaths
occurring in developing countries in 2015.5 RSV GOLD
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Figure 3: Age distribution at the time of RSV-related death in children
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RSV=respiratory syncytial virus.

is the first descriptive study of global RSV-related
mortality using individual case records. We studied
clinical characteristics of children who died with RSV in
hospitals across the world. We supplemented data from
e989

previously published cases of RSV-related in-hospital
death with unpublished data by contacting individual
investigators, research groups, and networks. Complete
clinical information was generally available for children
from high-income countries, but clinical data from lowincome and middle-income countries were often
incomplete. For the first time, we showed that a
substantial proportion of in-hospital RSV-related deaths
in young children occurred in those with severe
comorbidities. In low-income and middle-income
countries, most children who died with RSV infection
were aged younger than 6 months.
This study describes, to our knowledge, the largest
number of children with RSV-related mortality to date.
We obtained good global representation, with coverage of
all six continents. Clinical profiles of children who die
with RSV are essentially different in lower-income
countries, where most childhood RSV-associated
mortality occurs.1,5 In low-income or lower middle-income
countries, we found that at least 28% of deaths occurred
in children with severe comorbidities, such as congenital
heart disease. Our data suggest that most RSV-related inhospital deaths in both low-income and middle-income
countries occur in children aged younger than 6 months.
Most children with comorbidities (eg, severe prematurity
or congenital heart disease) in these countries might
already have died during neonatal age. Additionally, a
longer time interval between the onset of symptoms and
admission to hospital in low-income countries than in
middle-income and high-income countries and a lower
proportion of children being admitted to intensive care
units and receiving mechanical ventilation in low-income
and middle-income countries than in high-income
countries suggest that high RSV mortality in these
countries might reflect limitations in health-care quality
or access to care rather than specific susceptibility of
the children. Young age at death of children with
comorbidities in low-income and middle-income
countries might have been related to low access to care as
well. Paediatric intensive care was available to only 24% of
children from low-income or lower middle-income
countries and to most children from upper middleincome countries, although only 48% of these children
were actually admitted to the intensive care unit.
The role of comorbidities in RSV-related childhood
mortality has mostly been described in high-income
countries.10,11,24 The differences in characteristics of
children with or without comorbidities were in line with
previously published data from high-income settings.
Previous studies10,11,13,14,25,26 have also described a higher age
of children with comorbidities at admission or death
than of previously healthy children, whereas young age is
a risk factor for severe RSV disease in otherwise healthy
preterm children.27 For high-income countries, we
substantiate that the age distribution of children who die
with RSV infection is substantially different between
children with and without severe comorbidities.
www.thelancet.com/lancetgh Vol 5 October 2017
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Several strategies to prevent RSV infection and
RSV-related mortality are being developed.28 Age at
death could influence the effectiveness of perinatal
immunisation strategies, including passive immun
isation by maternal vaccination during pregnancy and
administration of RSV-specific long-half-life monoclonal
antibody at birth. Our age distribution data suggest that
maternal vaccination will be more effective for healthy
term children than for children with comorbidities
because antibody concentrations decrease after birth over
time. Our data suggest that children with comorbidities
will need additional preventive interventions, such as
extended passive immunisation or infant vaccination to
optimise prevention of RSV-related mortality.
A key strength of this study is that we obtained most
previously published cases of RSV-related mortality in
children and supplemented this data with data sourced
through existing networks, leading to a sample size large
enough to draw robust conclusions and do some sensitivity
analyses. Second, we verified the quality of each case
record through direct interaction with the local researchers.
Finally, RSV GOLD is a case series with global represen
tation. Limitations also deserve discussion. First, although
RSV GOLD forms, to our knowledge, the largest case
series of RSV-related childhood mortality in hospital, this
case series still reflects only a small proportion of all
RSV-related deaths worldwide, as most global acute lower
respiratory tract infection deaths occur outside of hospital.29
Data are scarce for RSV-related deaths in the community.
Second, in RSV GOLD, only 117 (33%) of the children
studied were from low-income or lower middle-income
countries, which contrasts with the estimate that 99% of
RSV-related mortality occurs in developing countries.5
Third, RSV GOLD is a case series, which does not allow
for calculation of effect sizes of risk factors for
RSV-associated mortality. A population-based study16 from
Buenos Aires reported sepsis and pneumothorax as
clinical risk factors for RSV-associated mortality, although
sepsis was not pathogen specific. To calculate risk ratios
for global RSV-related death with use of original case
records, a large prospective population-based study would
be needed, which would be challenging given the
estimated RSV-attributable mortality rate of 0·86–0·94 per
1000 livebirths.16 Fourth, our data are limited by several
biases. Data are primarily from research sites with
availability of diagnostic tests for RSV and RSV diagnostics
changing over time, with more sensitive molecular
diagnostics used after 2005 than before 2005 (selection
bias). Differences in the proportion of available data
between income regions could have caused additional
selection bias. For example, white blood count and
haemoglobin concentration were more often available in
low-income
regions,
which
probably
reflects
measurements in a clinical research setting. Some authors
who published data for RSV-related deaths did not respond
(response bias), and data for prematurity and comorbidities
were often missing, particularly from low-income and
www.thelancet.com/lancetgh Vol 5 October 2017

middle-income countries (misclassification bias).
Misclassification bias could have led to inaccurate
interpretation of results. The estimated prevalence of
comorbidities in children from low-income or lower
middle-income countries is probably an underestimation
caused by missing data for comorbidities, but could also
be an overestimation caused by selection bias due to a
research setting, for example. However, results from our
sensitivity analysis supported the main results of our study.
Finally, since a substantial proportion of sociodemographic
data were missing, these data should be interpreted with
caution. For example, the high proportion of RSV-related
deaths outside of the RSV season in some countries could
reflect inaccurate seasonality data, but could also result
from year-round RSV activity, as most of these countries
had subtropical climates.
RSV-related infection is an important cause of death in
children aged younger than 5 years. Data for RSV-related
deaths are scarce and, when available, these data are
limited to in-hospital deaths in research settings.
Additionally, data for some of the key variables, such as
comorbidities and gestational age, are missing. RSV
GOLD is being further expanded to collect data for RSVrelated deaths from any health facility or communitybased study worldwide. Investments to understand the
cause of death in young children need to be sustained to
inform vaccine policy, particularly in low-income and
middle-income settings.

For the expansion of the
respiratory syncytial virus
Global Online Mortality
Database see www.rsvgold.com
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